Medivir Promoted to NASDAQ OMX Stockholm Mid Cap List

Huddinge, Sweden - Medivir AB (OMX:MVIR), the emerging research-based specialty pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that NASDAQ OMX Stockholm is promoting Medivir AB (MVIR B) from the Small Cap to the Mid Cap List. The change is effective as of January 3, 2011.

Ron Long, CEO of Medivir commented, “Medivir has had a very successful year with many important operational, as well as financial milestones achieved during the year. The Medivir share price has performed strongly during 2010 and our ambition of creating value for our shareholders will continue. The move to the Mid Cap List is an important step for the Company’s future development.”

The NASDAQ Mid Cap List is for companies with a market cap between 150 million euro and 1 billion euro.

About Medivir
Medivir is a research-based specialty pharmaceutical company focused on the development of high-value treatments for infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development. Medivir has a strong R&D portfolio and has recently launched its first product Xerese™/Xerclear®. Medivir’s key pipeline asset, TMC435, a protease inhibitor, is in phase 2b clinical development for Hepatitis C and is partnered with Tibotec Pharmaceuticals. 

Xerese™/Xerclear® is an innovative treatment for cold sores, which has been approved in both the US and Europe. It is partnered with GSK to be sold OTC in Europe and Russia and with Meda in North America. Medivir has retained the Rx rights for Xerclear® in Sweden and Finland. 

Medivir’s key pipeline asset, TMC435, a protease inhibitor, is in phase 2b clinical development for Hepatitis C and is partnered with Tibotec Pharmaceuticals.

For more information about Medivir, please visit the Company’s website: www.medivir.se.